EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

2-Hydroxypropyl-β-cyclodextrin, solubiliser in a novel dantrolene formulation: Its binding affinities to clinical compounds that may be used during anaesthesia or management of malignant hyperthermia

Richard H Ng Kwet Shing, David J Wright, Sandeep Pal, Samuel L Smith, Lucy B Clayton, Jonathan G Bilmen

European Journal of Pharmaceutics and Biopharmaceutics · 2025

DOI: 10.1016/j.ejpb.2025.114765 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2025. Verfasst von Richard H Ng Kwet Shing und 5 weiteren Autor:innen. Beteiligte Einrichtung: Norgine Ltd, ARC Uxbridge, Building 01, Second Floor, Sanderson Road, Uxbridge UB8 1DH, UK. Electronic address: RNg@norgine.com. Hauptthemen laut MEDLINE: 2-Hydroxypropyl-beta-cyclodextrin, Dantrolene, Malignant Hyperthermia, beta-Cyclodextrins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Norgine Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

2-Hydroxypropyl-β-cyclodextrin (HP-β-CD) is used as an excipient to improve the solubility of the highly lipophilic drug dantrolene in a novel formulation, NPJ5008. Dantrolene acts as an antidote for life-threatening anaesthesia-associated malignant hyperthermia (MH) crises and intervention speed is essential to minimise morbidity. NPJ5008 can be prepared and administered substantially faster than DANTRIUM IV in a smaller volume of fluid. Like other cyclodextrins in clinical use, HP-β-CD forms inclusion complexes with lipophilic molecules. The potential of HP-β-CD to unintentionally interact in vivo with other drugs administered during anaesthesia or an MH emergency was assessed. An in silico predictive model of HP-β-CD binding was built from published data using LigPrep/Glide and GROMACS for molecular dynamic simulations to generate data for binding free energy calculations, performed with the molecular mechanics Poisson-Boltzmann surface area method using a thermodynamic cycle. Docking of >70 anaesthesia-relevant compounds with HP-β-CD was evaluated and 10 compounds were predicted to bind HP-β-CD using a cut-off of -4 kcal mol-1. In vitro isothermal titration calorimetry (37 °C, pH 7) was also used to determine the enthalpy of interaction of HP-β-CD with 18 of the most clinically relevant compounds, including rocuronium, vecuronium and remifentanyl (the strongest predicted binder from the in silico work). All had low injection heats with assay parameters of 1500 µM test compound and 50 µM HP-β-CD, i.e. there was no discernible binding to HP-β-CD. Thus, the HP-β-CD component of NPJ5008 is unlikely to interfere with other drugs clinically relevant in MH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

2-Hydroxypropyl-beta-cyclodextrinDantroleneMalignant Hyperthermiabeta-CyclodextrinsSolubilityHumansExcipientsMolecular Dynamics SimulationChemistry, PharmaceuticalMuscle Relaxants, CentralAnesthesia

Stichwörter der Autor:innen

2-Hydroxypropyl-beta-cyclodextrin (HP-β-CD)AnaesthesiaCyclodextrin interactionsDantrolene sodiumDrug–drug interactionExcipient safetyIsothermal titration calorimetry (ITC)Malignant hyperthermiaMolecular dynamicsMolecular mechanics Poisson–Boltzmann surface area (MM-PBSA)

Substanzen

2-Hydroxypropyl-beta-cyclodextrinDantroleneExcipientsbeta-CyclodextrinsMuscle Relaxants, Central

Autor:innen und Institutionen

  • Norgine Ltd, ARC Uxbridge, Building 01, Second Floor, Sanderson Road, Uxbridge UB8 1DH, UK. Electronic address: RNg@norgine.com.
  • Concept Life Sciences, Number Nine the BioQuarter, 9 Little France Road, Edinburgh EH16 4UX, UK. Electronic address: David.Wright@conceptlifesciences.com.
  • Cheminfo Solutions Ltd, 12 Bradleys Corner, Hitchin SG4 0PR, UK. Electronic address: spal@cheminfosolutions.co.uk.
  • Norgine Ltd, ARC Uxbridge, Building 01, Second Floor, Sanderson Road, Uxbridge UB8 1DH, UK. Electronic address: SSmith@Norgine.com.
  • Norgine Ltd, ARC Uxbridge, Building 01, Second Floor, Sanderson Road, Uxbridge UB8 1DH, UK. Electronic address: LClayton@norgine.com.
  • St. James' University Hospital, Clinical Science Block, Beckett Street, Leeds LS9 7TF, UK. Electronic address: jonathanbilmen@nhs.net.

Förderung

  • Norgine Ltd

Zitieren

APA

Ng Kwet Shing, R. H., Wright, D. J., Pal, S., Smith, S. L., Clayton, L. B., & Bilmen, J. G. (2025). 2-Hydroxypropyl-β-cyclodextrin, solubiliser in a novel dantrolene formulation: Its binding affinities to clinical compounds that may be used during anaesthesia or management of malignant hyperthermia. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2025.114765

Vancouver

Ng Kwet Shing RH, Wright DJ, Pal S, Smith SL, Clayton LB, Bilmen JG. 2-Hydroxypropyl-β-cyclodextrin, solubiliser in a novel dantrolene formulation: Its binding affinities to clinical compounds that may be used during anaesthesia or management of malignant hyperthermia. European Journal of Pharmaceutics and Biopharmaceutics. 2025. doi:10.1016/j.ejpb.2025.114765

BibTeX
@article{NgKwetShing2025,
  author = {Ng Kwet Shing, Richard H and Wright, David J and Pal, Sandeep and Smith, Samuel L and Clayton, Lucy B and Bilmen, Jonathan G},
  title = {2-Hydroxypropyl-β-cyclodextrin, solubiliser in a novel dantrolene formulation: Its binding affinities to clinical compounds that may be used during anaesthesia or management of malignant hyperthermia},
  journal = {European Journal of Pharmaceutics and Biopharmaceutics},
  year = {2025},
  doi = {10.1016/j.ejpb.2025.114765}
}
Kostenlos starten →